Last reviewed 2026-05-28 · How we verify

Sub Lingual Ticagrelor

Sheba Medical Center · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

Sub Lingual Ticagrelor is a Small molecule drug developed by Sheba Medical Center. It is currently FDA-approved.

Sublingual Ticagrelor is a small molecule that acts as a negative allosteric modulator of the P2Y purinoceptor 12, a type of purinergic receptor. It is used to treat conditions such as Acute Coronary Syndromes and Non ST Elevation Myocardial Infarction, and is administered sublingually.

At a glance

Generic name	Sub Lingual Ticagrelor
Sponsor	Sheba Medical Center
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Sub Lingual Versus Traditional Oral Administration of Ticagrelor in Acute Coronary Syndrome/Non ST-elevation Myocardial Infarction - A Platelet Reactivity Study (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Sub Lingual Ticagrelor CI brief — competitive landscape report
Sub Lingual Ticagrelor updates RSS · CI watch RSS
Sheba Medical Center portfolio CI

Frequently asked questions about Sub Lingual Ticagrelor

What is Sub Lingual Ticagrelor?

Sub Lingual Ticagrelor is a Small molecule drug developed by Sheba Medical Center.

Who makes Sub Lingual Ticagrelor?

Sub Lingual Ticagrelor is developed and marketed by Sheba Medical Center (see full Sheba Medical Center pipeline at /company/sheba-medical-center).

What development phase is Sub Lingual Ticagrelor in?

Sub Lingual Ticagrelor is FDA-approved (marketed).

Manufacturer: Sheba Medical Center — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing